ALKERMES, INC.
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06843590
- Locations
- 🇺🇸
Alkermes Investigational Site, San Antonio, Texas, United States
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
- Conditions
- Narcolepsy Type 1Narcolepsy Type 2Idiopathic Hypersomnia
- Interventions
- Drug: ALKS 2680, 4mgDrug: ALKS 2680, 10mgDrug: ALKS 2680, 6mgDrug: ALKS 2680, 14mgDrug: ALKS 2680, 8mgDrug: ALKS 2680, 18mg
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 256
- Registration Number
- NCT06767683
- Locations
- 🇺🇸
Alkermes Investigational Site, San Antonio, Texas, United States
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06555783
- Locations
- 🇦🇺
Alkermes Investigator Site, Bedford Park, South Australia, Australia
🇳🇱Alkermes Investigational Site, Zwolle, Netherlands
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06358950
- Locations
- 🇪🇸
Alkermes Investigational Site, Madrid, Spain
🇦🇺Alkermes Investigator Site, Bedford Park, South Australia, Australia
Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05547100
- Locations
- 🇺🇸
Alkermes Investigator Site, Las Vegas, Nevada, United States
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Conditions
- Bipolar I DisorderSchizophrenia
- Interventions
- Drug: OLZ/SAM
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT05303064
- Locations
- 🇲🇽
Alkermes Investigator Site, Monterrey, Mexico
🇺🇸Alkermes Investigational Site, Richmond, Virginia, United States
Phase 1 ALKS 1140 in Healthy Adults
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05019105
- Locations
- 🇦🇺
Alkermes Clinical Investigative Site, Brisbane, Australia
Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder
- Conditions
- Bipolar I Disorder
- Interventions
- Drug: OLZ/SAM
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04987658
- Locations
- 🇺🇸
Alkermes Investigational Site, Decatur, Georgia, United States
🇺🇸Alkermes Clinical Investigative Site, Cincinnati, Ohio, United States
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
- Conditions
- SchizophreniaBipolar I Disorder
- Interventions
- Drug: OLZ/SAM
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT04987229
- Locations
- 🇲🇽
Alkermes Investigational Site, Culiacán, Sinaloa, Mexico
A 28 Day Parallel Group Study to Assess the Effects of RDN-929
- Conditions
- Healthy
- Interventions
- Drug: Placebo oral capsuleDrug: RDN-929 oral capsule
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03963973
- Locations
- 🇳🇱
Brain Research Center, Amsterdam, Netherlands
🇳🇱QPS Netherlands B.V., Leeuwarden, Netherlands